REPLIGEN CORPORATION Funds and ETFs Repligen Corporation
Equities
RGEN
US7599161095
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.6 USD | +0.56% |
|
+6.01% | -7.35% |
ETFs positioned on Repligen Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.43% | 5 M€ | -1.80% | - | |
| 1.01% | 0 M€ | 0.00% | - | |
| 0.84% | 0 M€ | 0.00% | - | |
| 0.55% | 2 M€ | -.--% | ||
| 0.49% | 8 M€ | +2.44% | ||
| 0.43% | 509 M€ | -.--% | ||
| 0.21% | 4,592 M€ | +11.18% | ||
| 0.11% | 9 M€ | -.--% | - | |
| 0.09% | 2 M€ | +20.44% | - | |
| 0.09% | 3,859 M€ | +18.82% | - | |
| 0.09% | 469 M€ | -2.05% | - | |
| 0.08% | 9 M€ | +6.26% | - | |
| 0.06% | 736 M€ | +6.09% | ||
| 0.06% | 9 M€ | +2.75% | - | |
| 0.06% | 33 M€ | +0.25% | - | |
| 0.06% | 18 M€ | +3.41% | - | |
| 0.06% | 8 M€ | +3.41% | - | |
| 0.05% | 1,448 M€ | -.--% | - | |
| 0.05% | 219 M€ | +17.17% | - | |
| 0.05% | 330 M€ | -.--% | - | |
| 0.04% | 2 M€ | +14.69% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 23 M€ | -.--% | - | |
| 0.03% | 786 M€ | -.--% | ||
| 0.02% | 322 M€ | +13.88% | - | |
| 0.02% | 29 M€ | -.--% | - | |
| 0.02% | 35 M€ | +9.63% | - | |
| 0.02% | 206 M€ | -.--% | ||
| 0.02% | 284 M€ | -.--% |
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Companyâs chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Companyâs TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Calendar
2024-04-30
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
166.6
USD
Average target price
210.9
USD
Spread / Average Target
+26.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.35% | 9.3B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- RGEN Stock
- Funds and ETFs Repligen Corporation
